AVITA Medical (RCEL) Q2 2026 earnings review
Growth Accelerates and Cash Burn Plunges, Paving the Way to Breakeven
AVITA Medical delivered a breakout quarter, officially moving past its 2025 reimbursement disruptions. Revenue hit a record $21.7 million (up 18% YoY and 13% sequentially), driven by the core RECELL product and the accelerating adoption of Cohealyx and PermeaDerm. More importantly, operating discipline is taking hold: operating expenses declined 6% YoY, and net cash use plummeted to just $3.2 million from $9.9 million in Q1. Confident in this momentum, management raised full-year revenue guidance to $86-$89 million and expects to reach cash flow breakeven in Q4 2026.
🐂 Bull Case
Net cash use dropped dramatically to $3.2 million. Combined with a leaner, stable cost base ($24.6 million in OpEx, down 6% YoY), AVITA is showing real operating leverage that supports its Q4 breakeven target.
The transition from a single-product company is succeeding. Sequentially, RECELL grew 11%, Cohealyx grew 16%, and PermeaDerm surged 40%, proving the cross-selling strategy in core burn and trauma centers.
🐻 Bear Case
The company ended Q2 with just $11.1 million in cash. While cash burn is shrinking, any execution missteps before the Q4 breakeven target could force a dilutive capital raise.
While RECELL boasts an 86.0% gross margin, AVITA shares 50% and 60% of the Average Sales Price for Cohealyx and PermeaDerm, respectively. As these new products grow, they will dilute overall gross margin percentages.
⚖️ Verdict: 🟢
Bullish. Management promised an execution-led recovery and delivered. Reversing the demand destruction of 2025, raising guidance, and slashing cash burn proves the business model is stabilizing. Liquidity remains tight, but the trajectory is highly encouraging.
Key Themes
CMS Proposes National Medicare Framework
In a major regulatory win, CMS released proposed 2027 Medicare payment updates that would replace the fragmented regional Medicare Administrative Contractor (MAC) pricing with a transparent, national physician payment framework. It also proposes increases to hospital outpatient and ASC facility payment rates. This directly addresses the core vulnerability that caused the massive H1 2025 revenue disruption, removing future regional ambiguity.
Multi-Product Platform Synergies
The strategy to offer a comprehensive wound care portfolio is accelerating. While RECELL remains the anchor ($18.5M revenue), the newer products are gaining rapid traction. PermeaDerm grew 40% sequentially to $0.6M, and Cohealyx grew 16% to $1.7M. The ability to layer these complementary solutions into the existing 200 core U.S. accounts is increasing the revenue capture per patient without requiring additional sales headcount.
Rapid De-risking of Cash Burn
After burning $9.9 million in Q1, management promised a significant decrease and delivered an aggressive reduction to just $3.2 million in Q2. This was achieved through a stabilized cost structure and improved cash collections. This discipline validates the 2025 commercial restructuring (which reduced headcount from 108 to 82) and makes the Q4 cash flow breakeven target highly credible.
Dangerously Low Cash Buffer
Despite the impressive cash burn reduction, AVITA's liquidity profile is objectively fragile. The company ended Q2 with only $11.1 million in cash and marketable securities. They have access to a $10 million debt tranche, but it requires hitting $85 million in Trailing Twelve-Month (TTM) net revenue. If Q3 hits a seasonal speedbump, they risk a liquidity crunch before crossing the breakeven finish line.
Gross Margin Dilution from Growth Drivers
A structural contradiction exists in AVITA's growth narrative: the products growing the fastest carry the worst unit economics. The company shares 50% of the Average Sales Price (ASP) for Cohealyx and 60% for PermeaDerm. While total gross margin ticked up slightly YoY to 81.9%, it is heavily anchored by RECELL's 86.0%. As the newer products comprise a larger share of the pie, they will act as a permanent ceiling on overall margin expansion.
PermeaDerm Clinical Data Risk
PermeaDerm surged 40% sequentially, but it is currently positioned as a 'wound temporizer' alternative to allograft. Management noted that the critical PermeaDerm I clinical study data is expected in August. If this data fails to show that it is a clinically comparable, lower-cost alternative to traditional allografts, hospital Value Analysis Committees (VACs) may halt further approvals, reversing its current growth trajectory.
Other KPIs
Stable. Down 6% YoY. Demonstrates that the company can support 18% topline revenue growth without proportionally expanding its cost base. Sales and marketing expenses specifically saw a $0.7 million YoY reduction.
Accelerating improvement. Improved from -$9.9 million in the prior-year period and -$10.6 million in Q1 2026. This sequential and YoY narrowing is the direct result of gross profit dollars rising against a fixed operational cost ceiling.
Guidance
Accelerating. Raised from the prior range of $80.0 - $85.0 million. The new range implies year-over-year growth of 20% to 24% compared to FY25's $71.6 million, marking a robust recovery from the 11% growth rate posted in 2025.
Stable. Management reiterated their expectation to reach cash flow breakeven in the fourth quarter. Given the steep drop in cash use during Q2, this target now appears highly credible rather than aspirational.
Key Questions
Liquidity Contingencies
With only $11.1 million in cash remaining, how confident is management in triggering the $10 million debt tranche prior to Q4, and what is the contingency plan if working capital timing delays cash generation?
CMS 2027 Quantitative Impact
How will the proposed transition from MAC-priced models to a national physician relative value unit framework materially impact the blended Average Sales Price of the RECELL procedure?
PermeaDerm Data Readout
What specific endpoints in the upcoming August PermeaDerm I clinical study readout are deemed critical for unblocking broader hospital VAC approvals?